147 related articles for article (PubMed ID: 32730518)
1. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
[TBL] [Abstract][Full Text] [Related]
3. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.
Clement SC; van Eck-Smit BL; van Trotsenburg AS; Kremer LC; Tytgat GA; van Santen HM
Pediatr Blood Cancer; 2013 Nov; 60(11):1833-8. PubMed ID: 23832530
[TBL] [Abstract][Full Text] [Related]
5. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
Picco P; Garaventa A; Claudiani F; Gattorno M; De Bernardi B; Borrone C
Cancer; 1995 Nov; 76(9):1662-4. PubMed ID: 8635072
[TBL] [Abstract][Full Text] [Related]
6. Endocrine late effects from multi-modality treatment of neuroblastoma.
van Santen HM; de Kraker J; Vulsma T
Eur J Cancer; 2005 Aug; 41(12):1767-74. PubMed ID: 16039114
[TBL] [Abstract][Full Text] [Related]
7. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
8. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
[TBL] [Abstract][Full Text] [Related]
9. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
[TBL] [Abstract][Full Text] [Related]
10. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
[TBL] [Abstract][Full Text] [Related]
11. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
[TBL] [Abstract][Full Text] [Related]
12. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
14. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
15. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2003 Jul; 98(2):389-96. PubMed ID: 12872361
[TBL] [Abstract][Full Text] [Related]
16. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
19. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
20. Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.
Clement SC; Kraal KC; van Eck-Smit BL; van den Bos C; Kremer LC; Tytgat GA; van Santen HM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E112-6. PubMed ID: 24187404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]